Similar articles for PMID: 24111579

Year	Number of Results
2010	1
2011	5
2012	6
2013	17
2014	19
2015	12
2016	15
2017	15
2018	12
2019	8
2020	5
2021	11
2022	10
2023	7
2024	0

1

Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas.

Aalipour A, Advani RH. Aalipour A, et al. Br J Haematol. 2013 Nov;163(4):436-43. doi: 10.1111/bjh.12573. Epub 2013 Sep 24. Br J Haematol. 2013. PMID: 24111579 Free PMC article. Review.

2

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, Sukbuntherng J, Izumi R, Hamdy A, Hedrick E, Fowler NH. Advani RH, et al. J Clin Oncol. 2013 Jan 1;31(1):88-94. doi: 10.1200/JCO.2012.42.7906. Epub 2012 Oct 8. J Clin Oncol. 2013. PMID: 23045577 Free PMC article. Clinical Trial.

3

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.

Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, Buggy JJ. Honigberg LA, et al. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80. doi: 10.1073/pnas.1004594107. Epub 2010 Jul 6. Proc Natl Acad Sci U S A. 2010. PMID: 20615965 Free PMC article.

4

Ibrutinib and novel BTK inhibitors in clinical development.

Akinleye A, Chen Y, Mukhi N, Song Y, Liu D. Akinleye A, et al. J Hematol Oncol. 2013 Aug 19;6:59. doi: 10.1186/1756-8722-6-59. J Hematol Oncol. 2013. PMID: 23958373 Free PMC article. Review.

5

Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.

Wang Y, Zhang LL, Champlin RE, Wang ML. Wang Y, et al. Clin Pharmacol Ther. 2015 May;97(5):455-68. doi: 10.1002/cpt.85. Epub 2015 Apr 3. Clin Pharmacol Ther. 2015. PMID: 25669675 Review.

6

Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms.

Roskoski R Jr. Roskoski R Jr. Pharmacol Res. 2016 Nov;113(Pt A):395-408. doi: 10.1016/j.phrs.2016.09.011. Epub 2016 Sep 15. Pharmacol Res. 2016. PMID: 27641927 Review.

7

Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas.

Alinari L, Quinion C, Blum KA. Alinari L, et al. Clin Pharmacol Ther. 2015 May;97(5):469-77. doi: 10.1002/cpt.65. Epub 2015 Jan 20. Clin Pharmacol Ther. 2015. PMID: 25670208 Review.

8

Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase.

Davids MS, Brown JR. Davids MS, et al. Future Oncol. 2014 May;10(6):957-67. doi: 10.2217/fon.14.51. Future Oncol. 2014. PMID: 24941982 Free PMC article. Review.

9

Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.

Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, Codega P, Nichol D, Clark O, Hsieh WY, Rohle D, Rosenblum M, Viale A, Tabar VS, Brennan CW, Gavrilovic IT, Kaley TJ, Nolan CP, Omuro A, Pentsova E, Thomas AA, Tsyvkin E, Noy A, Palomba ML, Hamlin P, Sauter CS, Moskowitz CH, Wolfe J, Dogan A, Won M, Glass J, Peak S, Lallana EC, Hatzoglou V, Reiner AS, Gutin PH, Huse JT, Panageas KS, Graeber TG, Schultz N, DeAngelis LM, Mellinghoff IK. Grommes C, et al. Cancer Discov. 2017 Sep;7(9):1018-1029. doi: 10.1158/2159-8290.CD-17-0613. Epub 2017 Jun 15. Cancer Discov. 2017. PMID: 28619981 Free PMC article. Clinical Trial.

10

Ibrutinib and indolent B-cell lymphomas.

Akinleye A, Furqan M, Adekunle O. Akinleye A, et al. Clin Lymphoma Myeloma Leuk. 2014 Aug;14(4):253-60. doi: 10.1016/j.clml.2013.11.005. Epub 2013 Nov 15. Clin Lymphoma Myeloma Leuk. 2014. PMID: 24445187 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

126 results

Results by year